I-Lyrica (pregabalin) iyisidakamizwa esisetshenziselwa ukuphatha ubuhlungu be- fibromyalgia . Ngaphezu kwalokho, i-FDA ivunyelwe ukusetshenziswa kwe- neuropathy yesifo sikashukela neuralgia ye-neuralgia (shingles). Kuyinto futhi imithi yokulwa nokuthunjwa.
I-FDA ivume uLyrica nge-fibromyalgia ngoJuni 2007, okwenza kube yizidakamizwa zokuqala ezivunyelwe lesi simo. Kuze kube manje, ayikho inguqulo yesi-Lyrica.
Isilingana esiseduzane yi-gabapentin, okuyinto uhlobo olujwayelekile lomuthi we-Neurontin, onomqondo ofana noLyrica. (Eqinisweni, uLyrica uvame ukubizwa ngokuthi "indodana yeNeurontin.") Nokho, izidakamizwa azifani, ngakho umzimba wakho ungaphendula ngokuhlukile kubo.
I-Lyrica manje ingenye yezidakamizwa ze-fibromyalgia ezivunyelwe i-FDA futhi yedwa kuphela ongahlukaniswa njenge-anti-depressant. Enye imithi i- Cymbalta (duloxetine) no- Savella (milnacipran) .
Indlela uLyrica Esebenza ngayo
I-Fibromyalgia ikholelwa ukuthi ihilela imizwa engaphezu kokusebenza nokuhlukunyezwa kwama- neurotransmitters (izithunywa zamakhemikhali) ezithumela imiyalezo, kufaka phakathi izibonakaliso zobuhlungu, phakathi kwamangqamuzana obuchopho.
Ososayensi abaqondi kahle ukuthi uLyrica uthuthukisa kanjani izimpawu ze-fibromyalgia. Kodwa-ke, lesi sidakamizwa sikholelwa ukuthi sinciphise izimpendulo ezithile ebuchosheni futhi simise izinzwa ezingaphezu kokusebenza ngokungahambi kahle. Kungase futhi kuthinte indlela esebenza ngayo nge-neurotransmitters ethile.
I-Lyrica ye-Fibromyalgia
Nakuba sekuvunyiwe iminyaka eminingana, ucwaningo luye lwaqhubeka eLyrica njengendlela yokwelashwa kwe-fibromyalgia.
Yiqiniso, ukuze kube yi-FDA evunyelwe, ukuhlolwa okuningi kwemitholampilo kwakudingeka kubonise ukuthi kungasiza ekuthuthukiseni ubuhlungu be-fibromyalgia , ukukhathala, kanye nekhwalithi yokuphila.
Nokho, i-Lyrica ayisebenzi kuwo wonke umuntu nge-fibromyalgia.
Eqinisweni, ukubuyekezwa okushicilelwe ngo-2016 kutholakale ukuthi iLyrica yayiphumelele ngokulinganisela ngamaphesenti angu-39 abahlanganyeli abathintekayo abathatha 300 mg ngosuku, namaphesenti angama-43 alabo abathatha 600 mg ngosuku. Lezo zibalo zibonakala zithembisekile kuze kube yilapho ubheka ukuthi amaphesenti angu-28 abantu abathwala i-placebo enza kanjalo.
Olunye ucwaningo lubonisa ukuthi izidakamizwa ezintathu ze-FDA-ezivunyiwe ze-fibromyalgia-i-Lyrica, i-Cymbalta, ne-Savella-zizo zonke ngokuphumelelayo ngokulinganayo. Ukuhlanganisa izidakamizwa ezimbili kungase kuzuze kakhulu, noma kunjalo. Ucwaningo olwenziwa ngo-2016 olwanyatheliswa emaphepheni U- Pain ukhombisa ukuthi ukuhlanganisa iLyrica ne-Cymbalta kungase kusebenze kangcono kunomuthi owodwa, futhi abalobi banxusa ucwaningo oluthe xaxa ezindaweni zokwelapha ezihlangene.
Isilinganiso
Isilinganiso esivamile saseLyrica se-fibromyalgia singama 300 mg kuya ku-600 mg ngosuku, umahluko phakathi kwamathani amabili noma amathathu. Ngokuvamile, odokotela batusa ukuqala ngesilinganiso esincane, esingaba ngu-75 mg kabili ngosuku, futhi besebenza kancane kancane kumthamo omkhulu.
Uma unquma ukuphuma eLyrica, khuluma nodokotela wakho ngendlela efanele yokuyeka. Kuyingozi ukuyeka ukuthatha uLyrica ngokuzumayo.
Okuqhamuka uma udla imishanguzo
Kubuyekezwa ngo-2016 kwephrofayili yezokuphepha yaseLyrica, abacwaningi bathola ukuthi imiphumela embi emibi ivame ukuba mncane ukulinganisa nokuthi abantu abaningi bakwazi ukubekezelela isikhathi eside.
Olunye ucwaningo lubonisa ukuthi abantu abangamaphesenti ayishumi kuphela abaye baphuma ngenxa yemiphumela emibi evela eLyrica kunokuba bevela endaweni ye-placebo.
Noma kunjalo, uhlu lwemiphumela emibi yilezi zinde. Ezinye zinzulu ngokwanele ukuthi kufanele uxhumane nodokotela wakho ngokushesha uma unayo. Zihlanganisa:
- Ukusabela okwe-allergen (ukuqhaqhazela, ukuwashaza, ukusabalala, ubuso obuvuvukile, izindebe noma ulimi)
- Ukukhathazeka / ukudideka
- Izinkinga zokuphuza
- Umbono ushintsho
- Ubuhlungu besifuba
- Ukunyakaza okungajwayelekile okungavumelani
- Ukulahlekelwa kwememori
- Ubuhlungu be-muscle, ububele noma ubuthakathaka
- Izidlova
- Ukulimaza okungavamile noma ukuphaphaza
- Imicabango yokuzibulala noma yokufa
- Imodi iyashintsha
Imiphumela emibi ejwayelekile yaseLyrica, ngokuvamile engadingi ukunakekelwa kwezokwelapha, kufaka:
- Ukuqokwa noma isifo sohudo
- Umlomo omile
- Izinwele
- Ukungalali
- I-nausea
- Inzuzo yesisindo
Ucwaningo luye lwabona ukuthi uLyrica akavami ukubambisana kabi nezinye izidakamizwa nokuthi kubonakala sengathi kuphephile uma kuhlangene nama-antidepressants.
Izwi kusuka
Wena nodokotela wakho yibo kuphela abangakwazi ukunquma ukuthi kufanele unikeze uLyrica uzame. Yazi ukuthi kungaba yindleko kanti izinkampani zomshuwalense ngeke zikhokhelwe.
Kungumqondo omuhle, uma uqala imithi emisha, ukuze umuthi wakho wezinhlanzi abheke uhlu lwakho lwezidakamizwa nganoma yikuphi ukuxhumana okungalungile okunokwenzeka. Ungase futhi uthathe ukucabangela ukugcina uhlu lwemiphumela emibi kakhulu ukuze ukwazi ukuveza ngokushesha ukuthi unayo yini eyingozi.
Imithombo:
Derry S, Cording M, Wiffen PJ, et al. I-pregabalin yobuhlungu e-fibromyalgia kubantu abadala. Idatha yeCochrane yokubuyekeza okuhlelekile. 2016 Sep 29; 9: CD011790. [I-Epub ngaphambi kokuphrinta]
I-Gerardi MC, i-Atzeni F, i-Batticciotto A, et al. Ukuphepha kwe-pregabalin ekwelapheni kwe-fibromyalgia. Umbono wochwepheshe mayelana nokuphepha kwezidakamizwa. 2016 Okthoba 11: 1-8. [I-Epub ngaphambi kokuphrinta]
> Gilron I, Chaparro LE, Tu D. Ubuhlungu. Ukuhlanganiswa kwe-pregabalin ne-duloxetine ye-fibromyalgia: isilingo esilawulwa ngokungahleliwe. 2016 Jul; 157 (7): 1532-40.
> Lee YH, Ingoma GG. Ukusebenza okuqhathaniswa nokubekezelelana kwe-duloxetine, pregabalin, kanye ne-milnacipran yokwelashwa kwe-fibromyalgia: inethiwekhi ye-bayesian yokuhlaziywa kwezilinganiso zokulawulwa okungahleliwe. I-Rheumatology international. 2016 Meyi; 36 (5): 663-72.
I-NIH Publication CHA. 04-5326